Analyst Price Target is $100.31
▲ +142.89% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $100.31, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 142.89% upside from the last price of $41.30.
Current Consensus is
The current consensus among 18 polled investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.